| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
|
Bipolar Disord
|
2005
|
4.94
|
|
2
|
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.
|
Bipolar Disord
|
2009
|
3.56
|
|
3
|
Course of illness, hippocampal function, and hippocampal volume in major depression.
|
Proc Natl Acad Sci U S A
|
2003
|
3.29
|
|
4
|
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
|
Bipolar Disord
|
2012
|
3.01
|
|
5
|
Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment.
|
Neuropsychopharmacology
|
2007
|
2.02
|
|
6
|
Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings.
|
Am J Psychiatry
|
2006
|
1.84
|
|
7
|
Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders.
|
Int J Neuropsychopharmacol
|
2010
|
1.56
|
|
8
|
Brain structural signature of familial predisposition for bipolar disorder: replicable evidence for involvement of the right inferior frontal gyrus.
|
Biol Psychiatry
|
2012
|
1.47
|
|
9
|
Oxidative stress markers in bipolar disorder: a meta-analysis.
|
J Affect Disord
|
2008
|
1.46
|
|
10
|
Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder.
|
J Clin Psychiatry
|
2004
|
1.42
|
|
11
|
Stress-induced structural remodeling in hippocampus: prevention by lithium treatment.
|
Proc Natl Acad Sci U S A
|
2004
|
1.37
|
|
12
|
Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder.
|
Arch Gen Psychiatry
|
2010
|
1.36
|
|
13
|
Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder.
|
Int J Neuropsychopharmacol
|
2008
|
1.30
|
|
14
|
A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME].
|
J Clin Psychiatry
|
2012
|
1.30
|
|
15
|
Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study.
|
Psychopharmacology (Berl)
|
2007
|
1.17
|
|
16
|
Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder.
|
J Psychiatry Neurosci
|
2006
|
1.17
|
|
17
|
Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder.
|
Bipolar Disord
|
2003
|
1.16
|
|
18
|
Acute and chronic restraint stress alter the incidence of social conflict in male rats.
|
Horm Behav
|
2003
|
1.16
|
|
19
|
Treatment-specific changes in decentering following mindfulness-based cognitive therapy versus antidepressant medication or placebo for prevention of depressive relapse.
|
J Consult Clin Psychol
|
2012
|
1.15
|
|
20
|
The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression.
|
Can J Psychiatry
|
2002
|
1.12
|
|
21
|
Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force.
|
Aust N Z J Psychiatry
|
2013
|
1.12
|
|
22
|
Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells.
|
Biol Psychiatry
|
2005
|
1.08
|
|
23
|
Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis.
|
Bipolar Disord
|
2012
|
1.02
|
|
24
|
Lithium response and genetic variation in the CREB family of genes.
|
Am J Med Genet B Neuropsychiatr Genet
|
2008
|
1.01
|
|
25
|
Glutathione S-transferase is a novel target for mood stabilizing drugs in primary cultured neurons.
|
J Neurochem
|
2004
|
0.99
|
|
26
|
The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.
|
Neuropsychobiology
|
2010
|
0.98
|
|
27
|
3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder.
|
J Psychiatry Neurosci
|
2009
|
0.97
|
|
28
|
Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia.
|
Bipolar Disord
|
2009
|
0.97
|
|
29
|
Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2005
|
0.95
|
|
30
|
Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses.
|
Int J Neuropsychopharmacol
|
2010
|
0.95
|
|
31
|
Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study.
|
J Psychiatry Neurosci
|
2012
|
0.93
|
|
32
|
Desipramine treatment reduces the long-term behavioural and neurochemical sequelae of early-life maternal separation.
|
Int J Neuropsychopharmacol
|
2003
|
0.93
|
|
33
|
A pilot study of visual backward masking performance among affected versus unaffected offspring of parents with bipolar disorder.
|
Bipolar Disord
|
2004
|
0.91
|
|
34
|
Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment.
|
Bipolar Disord
|
2012
|
0.90
|
|
35
|
Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia.
|
Int J Neuropsychopharmacol
|
2011
|
0.90
|
|
36
|
Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells.
|
Life Sci
|
2005
|
0.90
|
|
37
|
A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression.
|
World J Biol Psychiatry
|
2011
|
0.89
|
|
38
|
Longitudinal outcome in patients with bipolar disorder assessed by life-charting is influenced by DSM-IV personality disorder symptoms.
|
Bipolar Disord
|
2003
|
0.89
|
|
39
|
Regulation of ER stress proteins by valproate: therapeutic implications.
|
Bipolar Disord
|
2002
|
0.89
|
|
40
|
cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment.
|
J Neurochem
|
2002
|
0.88
|
|
41
|
Is bipolar disorder a mitochondrial disease?
|
J Psychiatry Neurosci
|
2007
|
0.88
|
|
42
|
Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function.
|
Curr Psychiatry Rep
|
2013
|
0.86
|
|
43
|
Advances in bipolar disorder: selected sessions from the 2011 International Conference on Bipolar Disorder.
|
Ann N Y Acad Sci
|
2011
|
0.86
|
|
44
|
Neuroprotective effects of antidepressant and mood stabilizing drugs.
|
J Psychiatry Neurosci
|
2002
|
0.86
|
|
45
|
Cortical inhibitory dysfunction in bipolar disorder: a study using transcranial magnetic stimulation.
|
J Clin Psychopharmacol
|
2007
|
0.85
|
|
46
|
A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder.
|
Biol Psychiatry
|
2012
|
0.85
|
|
47
|
Immunoreactivity of 43 kDa growth-associated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia.
|
Neurosci Lett
|
2006
|
0.84
|
|
48
|
Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy.
|
CNS Drugs
|
2002
|
0.84
|
|
49
|
Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder.
|
Int J Neuropsychopharmacol
|
2013
|
0.83
|
|
50
|
Identification of lithium-regulated genes in cultured lymphoblasts of lithium responsive subjects with bipolar disorder.
|
Neuropsychopharmacology
|
2004
|
0.83
|
|
51
|
Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder.
|
J Psychiatry Neurosci
|
2007
|
0.83
|
|
52
|
Alterations in phosphorylated cAMP response element-binding protein (pCREB) signaling: an endophenotype of lithium-responsive bipolar disorder?
|
Bipolar Disord
|
2013
|
0.83
|
|
53
|
Chronic lithium treatment inhibits pilocarpine-induced mossy fiber sprouting in rat hippocampus.
|
Neuropsychopharmacology
|
2003
|
0.82
|
|
54
|
Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells.
|
Biol Psychiatry
|
2003
|
0.81
|
|
55
|
Immunological and neurotrophic markers of risk status and illness development in high-risk youth: understanding the neurobiological underpinnings of bipolar disorder.
|
Int J Bipolar Disord
|
2014
|
0.81
|
|
56
|
Abstinence from repeated amphetamine treatment induces depressive-like behaviors and oxidative damage in rat brain.
|
Psychopharmacology (Berl)
|
2013
|
0.81
|
|
57
|
Lithium reduces the effects of rotenone-induced complex I dysfunction on DNA methylation and hydroxymethylation in rat cortical primary neurons.
|
Psychopharmacology (Berl)
|
2014
|
0.80
|
|
58
|
BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder.
|
J Psychiatry Neurosci
|
2008
|
0.80
|
|
59
|
The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future.
|
Bipolar Disord
|
2013
|
0.79
|
|
60
|
Insulin-like growth factor binding protein-2 expression is decreased by lithium.
|
Neuroreport
|
2006
|
0.79
|
|
61
|
Lamotrigine increases gene expression of GABA-A receptor beta3 subunit in primary cultured rat hippocampus cells.
|
Neuropsychopharmacology
|
2002
|
0.79
|
|
62
|
Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment.
|
Brain Res
|
2007
|
0.79
|
|
63
|
Signal transduction pathways in the pathophysiology of bipolar disorder.
|
Curr Top Behav Neurosci
|
2011
|
0.79
|
|
64
|
What exactly is a mood stabilizer?
|
J Psychiatry Neurosci
|
2004
|
0.78
|
|
65
|
Mood stabilizing drugs lamotrigine and olanzapine increase expression and activity of glutathione S-transferase in primary cultured rat cerebral cortical cells.
|
Neurosci Lett
|
2009
|
0.77
|
|
66
|
What is the best treatment for bipolar depression?
|
J Psychiatry Neurosci
|
2008
|
0.77
|
|
67
|
Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex.
|
Int J Neuropsychopharmacol
|
2011
|
0.77
|
|
68
|
Reply: To PMID 25052507.
|
Acta Psychiatr Scand
|
2015
|
0.75
|
|
69
|
Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated bipolar disorder guidelines.
|
Bipolar Disord
|
2013
|
0.75
|
|
70
|
Fewer classes of drugs for more and more psychiatric disorders.
|
J Psychiatry Neurosci
|
2006
|
0.75
|
|
71
|
Applying molecular approaches to understand the etiology and treatment of bipolar disorder.
|
Can J Psychiatry
|
2007
|
0.75
|
|
72
|
Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder.
|
Bipolar Disord
|
2014
|
0.75
|
|
73
|
Psychosocial interventions for bipolar disorder and coping style modification: similar clinical outcomes, similar mechanisms?
|
Can J Psychiatry
|
2013
|
0.75
|
|
74
|
Glutathione-mediated effects of lithium in decreasing protein oxidation induced by mitochondrial complex I dysfunction.
|
J Neural Transm (Vienna)
|
2014
|
0.75
|